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Abstract
Background: Chronic primary musculoskeletal pain (CPMP) is one subcategory of the new classification of chronic
primary pain for the upcoming ICD-11, defined as chronic pain in the muscles, bones, joints, or tendons that
persists or recurs for more than 3 months and is associated with significant emotional distress or functional
disability. An array of pharmacological, psychological, physical, complementary, and rehabilitative interventions
is available for CPMP, for which previous research has demonstrated varying effect sizes with regard to
effectiveness in pain reduction and other main outcomes. This highlights the need for the synthesis of all
available evidence. The proposed network meta-analysis will compare all available interventions for CPMP to
determine the best treatment option(s) with a focus on efficacy and safety of interventions.
Methods: We are interested in comparing interventions of the following types: psychological,
pharmacological, physical, complementary, and rehabilitative interventions. We will include all randomized
controlled trials that compare one intervention with another, or with a control group, in the treatment of
CPMP. Primary efficacy outcomes will be pain intensity, emotional distress, and functional disability. Safety
outcomes extracted will include proportion of patients with treatment-emergent adverse events, unwanted
events, or drop-out rates due to side effects. Published and unpublished trials will be sought through the
search of all relevant databases and trial registries. At least two independent reviewers of the team will select
the references and extract data independently. We will assess the risk of bias of each individual study using
the Cochrane risk of bias assessment tool. We will conduct a network meta-analysis to synthesize all evidence
for each outcome. We will fit our model primarily within a Bayesian framework.
Discussion: CPMP is a disabling condition for which several interventions exist. To our knowledge, this is the
first network meta-analysis to systematically compare all available evidence. This is required by national health
institutions to inform their decisions about the best available treatment option(s) with regard to efficacy and
safety outcomes.
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Background
In 2015, an International Association for the Study of
Pain (IASP) Task Force, comprised of pain experts from
across the globe, suggested a new and pragmatic classifi-
cation of chronic pain for the upcoming ICD-11. This
classification includes seven categories, among them
chronic primary pain (CPP). This new definition was
created because the etiology for most pain conditions is
unknown; CPP describes a condition where pain itself is
the disease [1]. CPP is defined as pain in one or more
bodily regions that persists or recurs for more than 3
months, is associated with significant emotional distress
or functional disability, and is not better explained by
another chronic pain condition [2]. CPP consists of the
following subcategories: chronic widespread pain, complex
regional pain syndrome, chronic primary headache and
orofacial pain, and chronic primary visceral pain, as well
as chronic primary musculoskeletal pain [2]. These differ-
ent categories share the following multiple similarities that
allow to summarize them under the umbrella term CPP
[3–5]: (1) high comorbidity rates between chronic pain
conditions [6], (2) similar interventions across syndromes
[7], (3) similar psychiatric comorbidities (i.e., mainly anx-
iety and depression) [8], (4) similar societal challenges
(e.g., sick days and use of health care services) [9], and (5)
the syndromes share genetic factors [10].
The ICD-11 defines chronic primary musculoskeletal
pain (CPMP) as chronic pain in the muscles, bones, joints,
or tendons that is characterized by significant emotional
distress (i.e., anxiety, anger, frustration, and depressed
mood) or functional disability. CPMP poses a major prob-
lem of public health, considering its high prevalence and
refractory nature [11]. Low back pain and neck pain con-
tribute to 1694 years lost to disability per 100,000 persons
annually. The two disorders rank first and fourth as global
causes of years lived with disability [12]. These conditions
also reduce quality of life by interfering with work [11].
From a societal perspective, chronic musculoskeletal pain
creates substantial costs for healthcare systems, disability
insurance, and work absenteeism [13].
Interventions for CPMP include pharmacotherapy,
psychotherapeutic interventions, physiological therapies,
rehabilitative interventions, and complementary medicine.
Pharmacotherapy plays an important role in alleviating
pain for these patients. Non-steroidal anti-inflammatory
drugs (NSAIDs), muscle relaxants, and opioid analgesics
are some of the most common classes of drugs provided
[14]. With regard to effectiveness, pharmacological inter-
ventions show small to moderate effect sizes in recent
meta-analyses compared to placebo [14, 15]. For example,
Gabapentinoids showed minimal improvement of pain
when compared to placebo [16], and opioids showed bet-
ter pain reduction for chronic low back pain than placebo,
with standardized mean differences (SMDs) ranging
from − 0.55 for tramadol to − 2.47 for transdermal
buprenorphine, and strong opioids showed an SMD of
− 0.43 [17]. A network meta-analysis looking at paraceta-
mol, NSAIDs, and opioid analgesics is underway [18].
Additionally, vitamin D supplementation recently showed
no effect on pain (SMD= 0.004) [19]. It has been argued
that the small effects might be attributed to the choice of
the primary outcome measure (i.e., pain reduction) in
pharmacological trials [20]; other outcomes such as qual-
ity of life might show greater gains.
Non-pharmacological interventions also reveal small
to moderate effect sizes. For example, psychological in-
terventions such as CBT and self-regulatory treatments
proved superior to several control groups for pain inten-
sity (SMD = 0.41), pain interference (SMD = 0.23), and
quality of life (SMD = 0.41) at post-treatment [21]. Along
similar lines, a recent meta-analysis reported that a self-
management group for patients suffering from chronic
musculoskeletal pain revealed a moderate, significant
effect size (SMD = 0.28) when compared to a range of
control groups (such as waitlist control, treatment as
usual, exercise, and education); however, the difference
was not clinically significant [22]. Other meta-analyses
in the field of self-management training [23], multidis-
ciplinary biopsychosocial rehabilitation programs [24],
and pain education approaches [25] draw similar conclu-
sions. For physiological and alternative approaches, it
has been shown that Tai Chi is more effective than no
treatment or usual care in reducing pain in the short-
term (SMD = 0.66) [26]. Comparable effects have been
found for exercise interventions [27], whereas no signifi-
cant differences in pain were found between a Pilates
and a control group [28]. In terms of complementary
approaches, patients suffering from nonspecific chronic
low back pain reported a clinically meaningful reduction
in levels of pain when participating in an acupuncture
group [29]. However, it should be noted that the
pharmacological and non-pharmacological studies did
not use similar follow-up periods. Drug studies usually
have shorter timeframes than psychological ones, and a
direct comparison of the results is not advisable.
Besides effectiveness, the safety of a specific intervention
informs clinicians and guidelines. For example, Tapentadol
has shown to be associated with a 2.7-fold increase in the
risk of discontinuation treatment due to adverse effects
[15]. Non-pharmacological interventions may also cause
unwanted events but are, however, less frequent and less
likely to be reported. A meta-analysis of multicomponent
treatments (i.e., those that involve a combination of phys-
ical, psychological, educational, and/or work-related com-
ponents) looked at adverse events, but the included studies
reported adverse events in a manner that did not enable
comparisons between groups [24]. Other available meta-
analyses in the field of CPMP did not report safety
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outcomes, and to date, no network meta-analysis is avail-
able (except for one protocol [18] that looks at paracetamol,
NSAIDs, and opioid analgesics for chronic low back pain).
Aging and disability are both related to an increased
occurrence of chronic pain [30]. Despite increasing
awareness of the prevalence of pain among older adults,
under-treatment remains an issue, not only because of
polypharmacy and comorbid diseases, but also because
of commonly held pain myths which are assumed to com-
plicate care in the elderly [31]. To the best of our know-
ledge, meta-analyses focusing on this vulnerable age
category are scarce, with the exception of one recent
meta-analysis, examining exercise interventions in elderly
patients suffering from chronic musculoskeletal pain [32].
Previous research on efficacy and safety data has pre-
dominantly focused on the comparison of one medica-
tion versus a control group or has applied a comparative
design (e.g., the effectiveness and safety of one medica-
tion compared to another) [18]. However, from the per-
spective of patients and doctors selecting treatments, it
would be preferable to compare multiple interventions
simultaneously, and to quantify the likely range of out-
comes when selective between the highly diverse interven-
tions available. Here, the proposed network meta-analysis
uniquely allows to address these points.
Objectives
The objective of this systematic review and network meta-
analysis (NMA) is to synthesize all available data from
RCTs on interventions delivered for CPMP in adult pa-
tients, including the elderly. Our aims are to (1) compare
the efficacy (i.e., changes in pain, emotional distress, and
functional disability) and (II) safety (i.e., treatment-
emergent adverse events, serious adverse events, un-
wanted events) of all available interventions with each
other and various control groups. We will focus on post-
treatment assessment, medium-term, as well as long-term
follow-up, whereby long-term outcomes will be consid-
ered primary. Our analysis will incorporate information
on the relative efficacy of control interventions used
within included studies, and, where feasible, we will in-
clude control conditions within the matrix of treatment
comparisons (e.g., treatment-as-usual) [33].
Methods and analysis
Protocol and registration
Our protocol is registered on PROSPERO (CRD4
2018096114) and is available from http://www.crd.york.
ac.uk/PROSPERO.
Eligibility criteria for considering studies for review
Types of studies
We will include RCTs that make head-to-head compari-
sons of two different interventions as well as those that
compare an intervention with a control group (e.g.,
waitlist control, treatment as usual, or placebo) in the
treatment of CPMP. We will include protocols and
conference papers. Cross-over trials will be included
if the results of the first administration are reported
separately. Further, randomized single control studies
(e.g., the comparison of different dosages of one
intervention) will be included. Finally, prophylactic in-
terventions will be included and form a separate net-
work as long as they target CPMP.
We will not include case-control studies, post hoc ana-
lyses, or secondary analyses (for example those reporting
the cost-effectiveness of an intervention where the pri-
mary study focused on the efficacy of the intervention).
Types of participants
Adult patients, including the elderly, of both sexes, with
a primary diagnosis that can now be classified as CPMP
[2] will be included. We will classify chronic pain syn-
dromes as CPMP according to the 11th revision of the
International Classification of Diseases (ICD-11). Hence,
the syndromes to be included are now established as
chronic low back pain, chronic cervical pain, chronic
thoracic pain, and chronic limb pain. In line with the
ICD-11, we will only include patients suffering from pain
that occurs in one or more bodily regions and that persists
or recurs for more than 3months. Also, the diagnosis of
CPMP is appropriate independently of identified bio-
logical or psychological contributors unless another diag-
nosis would better account for the presenting symptoms.
Other ICD-11 chronic pain diagnoses, namely chronic
cancer-related pain, chronic postsurgical or posttraumatic
pain, chronic neuropathic pain, chronic secondary head-
ache or orofacial pain, chronic secondary visceral pain,
and chronic secondary musculoskeletal pain, will be ex-
cluded. Additionally, according to the ICD-11, CPMP is
characterized by significant emotional distress or func-
tional disability. However, the studies we include will rely
on older diagnostic criteria of chronic pain (e.g., DSM-III,
DSM-III-R, DSM-IV, DSM-5, and ICD-10). Therefore, we
will also include patients suffering from chronic pain
where no additional information regarding their emotional
or functional disability is provided.
Studies in which patients have a diagnosis of acute
pain (MG31), headache disorders (8A80-8A8Z), or a
chronic primary pain syndrome other than CPMP will
not be included. Also, studies reporting on chronic sec-
ondary pain (i.e., where pain is a symptom of an under-
lying condition) will be excluded.
Types of interventions
We will include all available interventions for CPMP.
This includes (but is not limited to) psychological inter-
ventions such as CBT, pharmacological agents such as
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opioid and non-opioid analgesics, physical interventions
such as exercise therapy, complementary interventions
such as acupuncture, and rehabilitative interventions
such as multidisciplinary inpatient treatment. We will
not only focus on face-to-face interventions, but also e-
health and m-health approaches. We do not require the
treatment to have a minimal length or to be provided by
a trained clinician. See the “Data extraction” section for
more details on what will be extracted from individual
studies.
Efficacy outcome measures
For each efficacy outcome, we plan to conduct a separate
NMA.
Primary outcomes
The choice of our primary outcomes is in line with rec-
ommendations for clinical trials studying chronic pain
(IMMPACT initiative) [34] as well as recent (network)
meta-analyses and reviews [15, 18, 35, 36] in the field.
Furthermore, we decided to focus on self-reported mea-
sures of pain rather than on clinical measurements (e.g.,
walking test) or objective measures (e.g., measure of pain
threshold) since first, self-report measures provide the
“gold standard” in the assessment of pain outcomes, and
second, to acknowledge the inherently subjective nature
of pain. Finally, we intend to prioritize global scores over
syndrome-specific scores since the definition of CPMP
includes various syndromes [37].
Global pain intensity and the global measurement of
pain will be our primary outcomes. We will extract both
outcomes where both are reported. We plan to model
them jointly, because we assume that these two mea-
surements correspond to the same underlying construct,
and relative intervention effects on each will be corre-
lated. We will conduct an additional sensitivity analysis
in which these outcomes will be analyzed separately.
1. Global pain intensity. Pain intensity may be
measured with a continuous self-report scale (e.g.,
visual analog scale (VAS) or numeric rating scale
(NRS)), or an ordinal scale with greater than six
levels (we will consider such ordinal scales to ex-
hibit continuous properties). It should be noted that
for the majority of clinical trials of CPP treatments,
a measure of pain intensity will provide the primary
outcome measure [34].
2. Global measurement of pain. A rating scale within a
composite measure of pain (e.g., Short-Form McGill
Pain Questionnaire (SF-MPQ) [38]).
In line with the core definition of CPMP (i.e., signifi-
cant emotional distress or functional disability), we de-
cided to define emotional distress as well as functional
disability as additional primary outcomes of interest.
Furthermore, the evaluation of additional symptoms
other than pain is clinically important since studies re-
veal that pain intensity and (physical) functioning are
only modestly associated [39].
3. Emotional distress. Emotional distress includes
symptoms such as depression, anxiety, and anger in
CPMP patients [40]. Questionnaires such as the
Beck Depression Inventory (BDI) [33], the Hospital
Anxiety and Depression Scale (HADS) [41], and the
Profile of Mood States (POMS) [42] will be
extracted.
4. Generic measures of functional disability.
Measurements of the interference of pain with
physical functioning. Use of global questionnaires
such as the Multidimensional Pain Inventory (MPI)
[43] as well as the Interference Scale or the Brief
Pain Inventory (BPI) [44, 45] with pain interference
items (i.e., general activity, mood, walking ability,
work, relations with other people, sleep, enjoyment
of life) will be extracted.
Secondary outcomes
The secondary outcomes are as follows:
1. Syndrome-specific pain. Self-rated questionnaires
which specifically measure pain in the field of
CPMP (e.g., the Aberdeen Back Pain Scale, ABPS
for chronic low back pain) [46].
2. Syndrome-specific measures of physical functioning.
Self-rated questionnaires which specifically evaluate
physical functioning for patients suffering from
chronic musculoskeletal pain (e.g., Roland and
Morris Back Pain Disability Scale for chronic low
back pain) [47].
3. Health-related quality of life (HRQOL). The SF-36
Health Survey [48] is the most commonly used
generic measure of HRQOL. However, we will also
extract other questionnaires such as the EuroQol
EQ-5D [49].
4. Participant ratings of global improvement and
satisfaction with treatment. This category will
evaluate all aspects of patients’ health and
assesses if there has been an improvement or
decline in clinical status (e.g., Patient Global
Impression of Change scale, PGIC) [50].
Safety outcome measures
For each safety outcome, we plan to conduct a separate
NMA.
Besides efficacy outcomes, we are also interested in
safety outcomes, including treatment-emergent adverse
events (TEAEs; e.g., dizziness and nausea), serious adverse
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events (SAEs; e.g., increased risk of suicidal thoughts and
behavior), and other unwanted events (UEs). Adverse
effects are described broadly as any of “adverse event,”
“adverse drug reaction,” “side effect,” “toxic effect,” “com-
plication,” and “unwanted events” that are associated with
the treatment under investigation (may it be pharmaco-
therapy, psychotherapeutic interventions, complementary
medicine, physiological therapies, or rehabilitative inter-
ventions). We will also extract the length of the treatment
period for each study in order to calculate the results for
the safety outcomes. We will evaluate three different
reporting methods of safety outcomes:
1. We will extract the proportion of patients who
experience TEAEs, SAEs, or UEs during the
treatment period (i.e., the latest reported time
point).
2. We will also extract the mean number of TEAEs,
SAEs, or UEs per patient across all reported
symptoms (i.e., for the latest reported time point).
3. Finally, study discontinuation due to TEAEs, SAEs,
or UEs is also defined as an additional safety
outcome measure.
Search strategy and study selection
Searches for published RCTs will be undertaken in the
following electronic databases: MEDLINE, Embase, Psy-
cINFO, Cochrane Central, and Web of Science. A first
search has been conducted until April 5th, 2018, and will
be updated in October 2019. In addition to that, we will
search for unpublished RCTs at clinicaltrials.gov and Open-
Trials. It is important to include unpublished data, since
publication bias leads to exaggerated effect sizes [51] and
reporting bias can bias NMA-based estimates of treatment
efficacy and modify ranking of interventions [52]. Studies
will be identified using search terms for chronic pain in
general (chronic pain) and specific syndromes (such as
fibromyalgia, complex regional pain syndromes, and irrit-
able bowel syndrome). See Additional file 1 for the search
strategy. Note that the search strategy also includes all
other categories of chronic primary pain (i.e., chronic wide-
spread pain, complex regional pain syndrome, chronic pri-
mary headache and orofacial pain, and chronic primary
visceral pain). The reasons for this are twofold: first, we
wanted to make sure that our search is exhaustive and sec-
ond, the long-term goal of this project is to build up a data-
base on all existing interventions for chronic primary pain
syndromes. Also, due to the high number of search returns,
each individual chronic primary pain category will be re-
ported separately. No data limits or language restrictions
will be applied to any of the searches. Results will be
exported into Covidence, a web-based software by
Cochrane to assist with the production of systematic re-
views (https://www.covidence.org).
A research team (i.e., around 15 people) will independ-
ently review references and abstracts retrieved by the search
and exported into Covidence (https://www.covidence.org/
home). The team will have a regular exchange (i.e., once in
a month) in order to clarify uncertainties and questions re-
lated to the screening process. Each paper will be evaluated
by two raters independently. Conflicts will be resolved by
the two primary investigators (CL and HK). Consensus will
be reached by a weekly consensus meeting of the two pri-
mary investigators. If no consensus can be reached, an in-
dependent expert in the field of CPP will be contacted. We
will obtain the full text of all articles included by reference
and abstract screening and use the same eligibility criteria
to determine inclusion or exclusion. In case of missing in-
formation on these domains in the article, the trial authors
may be contacted to obtain further information.
Data extraction
Each article/study-report will be read, evaluated for
completeness of the data and be rated for quality by two
independent reviewers (for quality ratings, see details
below). A structured data extraction form will be de-
signed and pilot-tested for 30 randomly selected studies.
Information extracted will include study design (type of
study such as parallel or cross-over design, blinding of
treatment, special inclusion criteria, special population
[if 80% or more of the sample share a particular characteris-
tic]), study characteristics (such as lead author, publication
year, journal, sponsor, region and setting, number of clinical
sites), participant characteristics (such as diagnostic criteria,
age, sex, pain syndrome, pain intensity, comorbidities, dur-
ation of symptoms, age of onset), intervention details (such
as type of intervention, drug dose and dosing schedule
[fixed vs. flexible], length of intervention, training of pro-
vider, co-intervention/prophylaxis), control group details
(such as type of control group, placebo lead-in yes/no, con-
trol dose and dosing schedule, length of control), analysis
details (such as intent-to-treat, secondary or sub-analysis),
and outcome measures (see the “Outcome measurements”
section). After the extraction, we will carefully check and
decide which demographics will be used for moderator
analyses.
Outcome measurements
We will extract means (Ms) and standard deviations
(SDs) for our continuous outcomes (i.e., efficacy out-
comes). We will also extract the number of events (E) as
well as the total occurrences (N) for each trial arm for
our categorical outcomes (i.e., safety outcomes). We will
extract data in a wide format (i.e., single study per row)
for both continuous and categorical outcomes (i.e., effi-
cacy and safety outcomes). Two review authors (HK and
CL) will ascertain that the data are entered correctly into
the final data set. We will evaluate whether published
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and unpublished studies provide different values, using
sensitivity analysis.
Missing outcome data
If SDs are not provided for the continuous outcomes, we
will calculate them from standard errors (SEs), confi-
dence intervals [53] or other measures [54, 55]. If we are
unable to calculate SDs, we will impute the mean of SDs
from studies using the same outcome measure [56]. It
should be noted that the SDs depend on the scale of
measurement which can vary between studies even for
the same outcome measure (e.g., VAS for global pain in-
tensity ranging from 1 to 10 or from 1 to 100). There-
fore, we will adapt the imputation procedure: SDs vs. Ms
will be plotted across all studies where SDs are provided.
This will allow us to use a regression model to more
precisely predict the SDs in studies without them, based
on the reported mean in that particular study. We will
conduct an additional sensitivity analysis (all studies, in-
cluding those with imputed SDs vs. only those studies
that report SDs). If the sensitivity analysis reveals a sig-
nificant difference, we will exclude studies with missing
SDs. If the N is missing in the table of analysis, we will
use the N of the descriptive statistics (e.g., patients ran-
domized). In the absence of continuous outcome data,
we will extract the number of patients that fulfilled a
certain criterion (e.g., pain relief) and the number of pa-
tients that did not fulfill the respective criterion [57].
Unit of analysis issues
For cross-over studies, only the first period before the
cross will be extracted [58]. In the case of cluster-
randomized trials, we will extract data that takes the
clustering into account (i.e., adjusted results). If such ad-
justed data are not available, we will extract unadjusted
results and will adjust the sample size by dividing it with
the design effect.
Length of trial
In line with other meta-analytical approaches [24, 59],
we will extract outcome assessment data for a maximum
of three time periods and group them for the purposes
of disseminating the analyses: post-treatment assessment
(i.e., measured at the time point closest to the end of
treatment), medium-term (i.e., at least 3 months but less
than 12months), and long-term follow-up (i.e., 12
months or more) measured from end of treatment. We
considered long-term outcomes to be primary.
Risk of bias in individual studies
We will assess risk of bias in the included studies using
the revised Cochrane risk of bias assessment tool [60].
The assessment will be performed by two raters inde-
pendently. Any disagreements will be resolved by the
primary investigators (HK and CL). The risk of bias will
be evaluated across the following domains: generation of
allocation sequence, allocation concealment, blinding of
study personnel and participants, blinding of outcome
assessor, attrition, selective outcome reporting, and
other domains, including sponsorship bias. We will con-
duct a sensitivity analysis and compare all studies vs.
only those studies with low or moderate risk of bias (i.e.,
excluding those with high risk of bias). We will pilot-test
the risk of bias assessment procedure on a small number
of studies.
Statistical synthesis of study data
Characteristics of included studies and information flow in
the network
We will present descriptive statistics for each trial, in-
cluding study characteristics (e.g., lead author, publica-
tion year, journal, sponsor, region and setting, number
of clinical sites) as well as participant characteristics
(e.g., diagnostic criteria, age, sex, pain syndrome, pain in-
tensity, comorbidities, duration of symptoms, age of on-
set). We will also describe the types of comparisons. The
available results will be presented in a network diagram
for each outcome. The size of the nodes will reflect the
amount of evidence accumulated for each treatment
(total number of patients), the breadth of each edge will
be proportional to the inverse of the variance of the
summary effect of each direct treatment comparison,
and the color of each edge will represent the risk of bias
assessment.
Pairwise meta-analyses
For the pairwise meta-analyses, mean differences of effi-
cacy outcomes (e.g., global pain intensity) between treat-
ment groups will be estimated for each study and will be
pooled using a standardized mean difference (SMD). In
the case where we have pre- and post-measures only
and we want to calculate the standard error (SE) for
change from baseline, a correlation coefficient (r) is
needed. In a first step, we will set r = 0.5. However, we
will conduct additional sensitivity analyses, defining
r = {0.3, 0.7} [56]. For our safety outcome measures, we
will calculate odds ratios (ORs) with 95% credible
intervals.
Heterogeneity will be assessed by calculating the Q
statistic, the τ2, and the I2, a transformation of Q that in-
dicates the proportion of observed variance that can be
attributed to heterogeneity rather than sampling error
[61, 62]. However, we will prefer Q statistic and the τ2
over the I2, as the I2 is sensitive to sample size [63].
Network meta-analyses
For the network meta-analyses of efficacy and safety out-
comes, we will employ Bayesian methods, using JAGS via R
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[64] using the R package gemtc (https://cran.r-project.org/
web/packages/gemtc/gemtc.pdf). Initially, we will set broad,
pessimistic, weakly informative priors for treatment effects
[65]. With regard to the nodes in the network, we plan to
start by splitting the interventions and plot networks in a
first step. However, this might lead to unconnected net-
works. Therefore, in a second step, we will discuss ways to
classify the interventions into groups, relying on clinical ex-
perts in this area to gain an understanding of the different
interventions. Other aspects such as length of sessions and
training of treatment providers will be included as regres-
sion covariates. In a sensitivity analysis, we will contrast this
with models using priors elicited from the study team and
our clinical colleagues.
We will calculate SMDs for our continuous efficacy
outcomes and risk (i.e., probability of study discontinu-
ation due to side effects) or rate ratios (i.e., proportion
of patients who experience TEAEs or SAEs and the
mean number of TEAEs and SAEs across all partici-
pants) for our categorical safety outcomes. We will
present the summary SMD as well as ORs for all pair-
wise comparisons in a league table. We will use random-
effects models rather than fixed-effects models because
we expect that the included studies will be heteroge-
neous [66]. However, we will assess heterogeneity and if
there is no evidence of heterogeneity, then a fixed-
effects model will be more appropriate.
In case of an unconnected network (e.g., two separate
networks for pharmacological and psychological inter-
ventions), we plan to conduct and report results from
each of the networks analyzed separately. We will also
use these statistical models to summarize likely efficacy
outcomes (and uncertainty in those outcomes) from the
perspective of a patient choosing between interventions.
Assessment of the transitivity assumption
The transitivity assumption states that we can combine
the direct evidence from AC and BC studies to learn (in-
directly) about the comparison AB [67]. We will evaluate
the assumption of the transitivity by epidemiologic judg-
ment considering three of its “equivalent expressions” by
Salanti [68, 69]: (1) whether studies are comparable in
terms of the distribution of effect modifiers, (2) whether
the direct and indirect treatment effects are in statistical
agreement (via an assessment for inconsistency), and (3)
whether participants included in the network could in
principle be randomized to any of the treatments.
Subgroup analyses
We will test whether some interventions have treatment
effects dependent on what syndrome and age group (i.e.,
adults vs. the elderly) they are being applied in. This will
add an extra level of hierarchy.
Sensitivity analyses
Multiple sensitivity analyses are planned and described
in the according paragraphs. In short, these include (1)
double-blind vs. unblinded trials (this is especially im-
portant for pharmacological interventions since there,
double-blinding is possible and preferable), (2) global
pain intensity vs. global measurement of pain (we will
analyze them separately in this sensitivity analysis in
order to justify the pooling across the two outcomes),
(3) published vs. unpublished, (4) imputed vs. reported
SD, (5) high risk of bias vs. low risk of bias, and (6) dif-
ferent levels of correlation coefficients where SE for
change from baseline has to be calculated (r = 0.5 vs.
r = {0.3, 0.7}).
Assessment of inconsistency
Transitivity will be tested with a statistical evaluation of
consistency, i.e., the agreement between direct and indir-
ect estimates. We will apply local as well as global
methods to detect inconsistency [67, 70, 71]. Local
methods focus on the inconsistency of a specific treat-
ment comparison, whereas global methods check for in-
consistency in the entire network of evidence [67, 71].
We will apply a local method to test for incoherence,
namely node-splitting, which compares direct and indir-
ect relative treatment effects using a Z-test [71] and a p
value of test for disagreement (direct versus indirect evi-
dence). In order to calculate node-splitting, we will use
the R package gemtc. We will also evaluate consistency
in the entire network by calculating the unrelated mean
effects (UME) model [71]. In this model, the consistency
equations are completely removed, which is equivalent
to a series of independent meta-analyses for each pair-
wise contrast while sharing a common heterogeneity
variance. The fit of this model is then compared with
the standard consistency NMA model [67]. It should be
noted that for both local and global approaches, it will
only be possible to assess inconsistency if the network
presents with closed loops.
Tests for inconsistency are known to have low power
[53, 72], and it has been reported that 10% of evidence
loops are expected to be inconsistent in the medical lit-
erature [73]. Accordingly, we plan to interpret the statis-
tical inference regarding inconsistency with caution.
Selection bias
We will apply the comparison-adjusted [53] as well as the
contour-enhanced [74] funnel plots in order to investigate
whether the results in imprecise trials significantly differ
from those in more precise trials. Additionally, we will
perform a meta-regression with a measure of study preci-
sion as a covariate, which allows us to explore if there are
issues with small study effects [75].
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Discussion
The introduction of the new CPMP classification in the
ICD-11 both enables and requires the generation of new
evidence regarding its treatment options. The network
meta-analytic approach will synthesize already existing
syndrome-specific evidence in a single network, resulting
in efficacy and safety outcomes of multiple interventions
for CPMP. Also, evidence gaps in the new field of CPMP
will be identified.
National organizations such as the National Institute
for Health and Care Excellence require the synthesis of
all available evidence from existing studies to inform
their decisions about the best available treatment op-
tion(s) with regard to safety and efficacy outcomes [76].
The planned network meta-analysis will provide these
organizations, clinicians, and patients with this informa-
tion, potentially helping to inform clinical guidelines.
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